	US 12,216,120 B2
	Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
James E. Crowe, Jr., Nashville, TN (US); Seth Zost, Nashville, TN (US); Robert Carnahan, Nashville, TN (US); and Pavlo Gilchuk, Nashville, TN (US)
Assigned to Vanderbilt University, Nashville, TN (US)
Filed by Vanderbilt University, Nashville, TN (US)
Filed on Mar. 18, 2022, as Appl. No. 17/655,503.
Application 17/655,503 is a division of application No. 17/212,949, filed on Mar. 25, 2021, granted, now 11,345,741.
Claims priority of provisional application 63/161,890, filed on Mar. 16, 2021.
Claims priority of provisional application 63/142,196, filed on Jan. 27, 2021.
Claims priority of provisional application 63/040,224, filed on Jun. 17, 2020.
Claims priority of provisional application 63/040,246, filed on Jun. 17, 2020.
Claims priority of provisional application 63/037,984, filed on Jun. 11, 2020.
Claims priority of provisional application 63/027,173, filed on May 19, 2020.
Claims priority of provisional application 63/024,248, filed on May 13, 2020.
Claims priority of provisional application 63/024,204, filed on May 13, 2020.
Claims priority of provisional application 63/023,545, filed on May 12, 2020.
Claims priority of provisional application 63/003,716, filed on Apr. 1, 2020.
Claims priority of provisional application 63/002,896, filed on Mar. 31, 2020.
Claims priority of provisional application 63/000,299, filed on Mar. 26, 2020.
Prior Publication US 2022/0281958 A1, Sep. 8, 2022
Int. Cl. C07K 16/10 (2006.01); A61P 31/14 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01)

CPC G01N 33/56983 (2013.01) [A61P 31/14 (2018.01); C07K 16/1002 (2023.08); C07K 16/1003 (2023.08); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/94 (2013.01)]

20 Claims

1. A method of treating a subject infected with SARS-COV-2 or reducing the likelihood of infection of a subject at risk of contracting SARS-COV-2, comprising administering to the subject a first antibody or antibody fragment comprising:

(a) a CDRH1 comprising the amino acid sequence of SEQ ID NO:59, a CDRH2 comprising the amino acid sequence of SEQ ID NO:60, a CDRH3 comprising the amino acid sequence of SEQ ID NO:61, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 89, a CDRL2 comprising the amino acid sequence of SEQ ID NO:90, a CDRL3 comprising the amino acid sequence of SEQ ID NO:91;

(b) a CDRH1 comprising the amino acid sequence of SEQ ID NO:68, a CDRH2 comprising the amino acid sequence of SEQ ID NO:69, a CDRH3 comprising the amino acid sequence of SEQ ID NO:70, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 98, a CDRL2 comprising the amino acid sequence of SEQ ID NO:99, a CDRL3 comprising the amino acid sequence of SEQ ID NO:100;

(c) a CDRH1 comprising the amino acid sequence of SEQ ID NO:41, a CDRH2 comprising the amino acid sequence of SEQ ID NO:42, a CDRH3 comprising the amino acid sequence of SEQ ID NO:43, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 71, a CDRL2 comprising the amino acid sequence of SEQ ID NO:72, a CDRL3 comprising the amino acid sequence of SEQ ID NO:73;

(d) a CDRH1 comprising the amino acid sequence of SEQ ID NO:44, a CDRH2 comprising the amino acid sequence of SEQ ID NO:45, a CDRH3 comprising the amino acid sequence of SEQ ID NO:46, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 74, a CDRL2 comprising the amino acid sequence of SEQ ID NO:75, a CDRL3 comprising the amino acid sequence of SEQ ID NO:76;

(e) a CDRH1 comprising the amino acid sequence of SEQ ID NO:47, a CDRH2 comprising the amino acid sequence of SEQ ID NO:48, a CDRH3 comprising the amino acid sequence of SEQ ID NO:49, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 77, a CDRL2 comprising the amino acid sequence of SEQ ID NO:78, a CDRL3 comprising the amino acid sequence of SEQ ID NO:79;

(f) a CDRH1 comprising the amino acid sequence of SEQ ID NO:50, a CDRH2 comprising the amino acid sequence of SEQ ID NO:51, a CDRH3 comprising the amino acid sequence of SEQ ID NO:52, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 80, a CDRL2 comprising the amino acid sequence of SEQ ID NO:81, a CDRL3 comprising the amino acid sequence of SEQ ID NO:82;

(g) a CDRH1 comprising the amino acid sequence of SEQ ID NO:53, a CDRH2 comprising the amino acid sequence of SEQ ID NO:54, a CDRH3 comprising the amino acid sequence of SEQ ID NO:55, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 83, a CDRL2 comprising the amino acid sequence of SEQ ID NO:84, a CDRL3 comprising the amino acid sequence of SEQ ID NO:85;

(h) a CDRH1 comprising the amino acid sequence of SEQ ID NO:56, a CDRH2 comprising the amino acid sequence of SEQ ID NO:57 a CDRH3 comprising the amino acid sequence of SEQ ID NO:58, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 86, a CDRL2 comprising the amino acid sequence of SEQ ID NO:87, a CDRL3 comprising the amino acid sequence of SEQ ID NO:88;

(i) a CDRH1 comprising the amino acid sequence of SEQ ID NO:62, a CDRH2 comprising the amino acid sequence of SEQ ID NO:63 a CDRH3 comprising the amino acid sequence of SEQ ID NO:64, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 65, a CDRL2 comprising the amino acid sequence of SEQ ID NO:66, a CDRL3 comprising the amino acid sequence of SEQ ID NO:67; or

(j) a CDRH1 comprising the amino acid sequence of SEQ ID NO:65, a CDRH2 comprising the amino acid sequence of SEQ ID NO:66, a CDRH3 comprising the amino acid sequence of SEQ ID NO:67, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 95, a CDRL2 comprising the amino acid sequence of SEQ ID NO:96, a CDRL3 comprising the amino acid sequence of SEQ ID NO:97.